EXPRESSION OF DIHYDROPYRIDINE RECEPTOR (CA-2+ CHANNEL) AND CALSEQUESTRIN GENES IN THE MYOCARDIUM OF PATIENTS WITH END-STAGE HEART-FAILURE

被引:174
|
作者
TAKAHASHI, T
ALLEN, PD
LACRO, RV
MARKS, AR
DENNIS, AR
SCHOEN, FJ
GROSSMAN, W
MARSH, JD
IZUMO, S
机构
[1] BETH ISRAEL HOSP, MOLEC MED UNIT, INDURSKY LAB MOLEC CARDIOL, BOSTON, MA 02215 USA
[2] BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA
[3] CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02114 USA
[4] BRIGHAM & WOMENS HOSP, DEPT ANESTHESIOL, BOSTON, MA 02114 USA
[5] BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02114 USA
[6] BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02114 USA
[7] HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA
[8] HARVARD UNIV, SCH MED, DEPT ANESTHESIOL, BOSTON, MA 02114 USA
[9] HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02114 USA
[10] CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA
关键词
DIHYDROPYRIDINE RECEPTOR; CALCIUM CHANNEL; CALCIUM ATPASE; CALSEQUESTRIN; HEART FAILURE; HUMAN CARDIAC TRANSPLANT;
D O I
10.1172/JCI115969
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cytoplasmic free calcium ions (Ca2+) play a central role in excitation-contraction coupling of cardiac muscle. Abnormal Ca2+ handling has been implicated in systolic and diastolic dysfunction in patients with end-stage heart failure. The current study tests the hypothesis that expression of genes encoding proteins regulating myocardial Ca2+ homeostasis is altered in human heart failure. We analyzed RNA isolated from the left ventricular (LV) myocardium of 30 cardiac transplant recipients with end-stage heart failure (HF) and five organ donors (normal control), using cDNA probes specific for the cardiac dihydropyridine (DHP) receptor (the alpha-1 subunit of the DHP-sensitive Ca2+ channel) and cardiac calsequestrin of sarcoplasmic reticulum (SR). In addition, abundance of DHP binding sites was assessed by ligand binding techniques (n = 6 each for the patients and normal controls). There was no difference in the level of cardiac calsequestrin mRNA between the HF patients and normal controls. In contrast, the level of mRNA encoding the DHP receptor was decreased by 47% (P < 0.001) in the LV myocardium from the patients with HF compared to the normal controls. The number of DHP binding sites was decreased by 35-48%. As reported previously, expression of the SR Ca2+-ATPase mRNA was also diminished by 50% (P < 0.001) in the HF group. These data suggest that expression of the genes encoding the cardiac DHP receptor and SR Ca2+-ATPase is reduced in the LV myocardium from patients with HF. Altered expression of these genes may be related to abnormal Ca2+ handling in the failing myocardium, contributing to LV systolic and diastolic dysfunction in patients with end-stage heart failure.
引用
收藏
页码:927 / 935
页数:9
相关论文
共 50 条
  • [41] Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+leak in human ventricular cardiomyocytes of patients with end-stage heart failure
    Eiringhaus, Joerg
    Wuensche, Christoph M.
    Tirilomis, Petros
    Herting, Jonas
    Bork, Nadja
    Nikolaev, Viacheslav O.
    Hasenfuss, Gerd
    Sossalla, Samuel
    Fischer, Thomas H.
    ESC HEART FAILURE, 2020, 7 (05): : 2992 - 3002
  • [42] Relaxin-2 may offer therapeutic advantages in end-stage heart failure
    Zhao, Zhiqiang
    Liu, Tong
    Li, Guangping
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 157 (03) : 432 - 433
  • [43] Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
    Cavalli, Giulio
    Foppoli, Marco
    Cabrini, Luca
    Dinarello, Charles A.
    Tresoldi, Moreno
    Dagna, Lorenzo
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [45] Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation
    Zern, Emily K.
    Cheng, Susan
    Wolfson, Aaron M.
    Hamilton, Michele A.
    Zile, Michael R.
    Solomon, Scott D.
    Kittleson, Michelle M.
    CIRCULATION-HEART FAILURE, 2020, 13 (02) : E006696
  • [46] Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
    Inampudi, Chakradhari
    Alvarez, Paulino
    Asleh, Rabea
    Briasoulis, Alexandros
    CURRENT CARDIOLOGY REVIEWS, 2018, 14 (01) : 60 - 66
  • [47] The effect of chronic mechanical circulatory support on neuroendocrine activation in patients with end-stage heart failure
    Noirhomme, P
    Jacquet, L
    Underwood, M
    El Khoury, G
    Goenen, M
    Dion, R
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1999, 16 (01) : 63 - 67
  • [48] Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure
    Bleeker, GB
    Schalij, MJ
    Molhoek, SG
    Verwey, HF
    Holman, ER
    Boersma, E
    Steendijk, P
    Van Der Wall, EE
    Bax, JJ
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2004, 15 (05) : 544 - 549
  • [49] The Utility of Pentraxin and Modified Prognostic Scales in Predicting Outcomes of Patients with End-Stage Heart Failure
    Szczurek-Wasilewicz, Wioletta
    Skrzypek, Michal
    Romuk, Ewa
    Gasior, Mariusz
    Szygula-Jurkiewicz, Bozena
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [50] The CardioMEMS system in the clinical management of end-stage heart failure patients: three case reports
    Carsten Tschöpe
    Alessio Alogna
    Frank Spillmann
    Alessandro Faragli
    Gunther Schmidt
    Florian Blaschke
    Uwe Kühl
    Ewa Hertel
    Monika Willner
    Daniel Morris
    Heiner Post
    Michel Noutsias
    Burkert Pieske
    Florian Krackhardt
    BMC Cardiovascular Disorders, 18